NIH JOINS FORCES WITH PRIVATE SECTOR TO STREAMLINE COVID VACCINE EFFORT
The National Institutes of Health (NIH) and major drug companies recently announced a plan to stage carefully designed clinical trials of the drugs and vaccines they have decided are the highest priorities for testing and development. The public-private partnership involves NIH, and other U.S. government agencies, 16 pharma companies and biotechs and the nonprofit Foundation for the National Institutes of Health (FNIH). The initiative, called Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV), aims to make efficient use of NIH funding and its clinical trial networks by working with companies to evaluate data on early candidates, selecting those that have the most promise and are not already part of rigorous human tests.